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Background
Immune checkpoint inhibition with anti–PD-1 monoclo-
nal antibodies such as pembrolizumab has demonstrated
robust, durable anti-tumor activity against many advanced
malignancies. We analyzed immune-related gene expres-
sion profiles in pembrolizumab-treated patients with
advanced solid tumors to identify immune gene signatures
correlated with clinical benefit.
Methods
RNA was extracted from formalin-fixed, paraffin-embedded
sections of baseline tumor samples and analyzed using a
custom 680-gene set on the NanoString nCounter plat-
form. A 10-gene preliminary “interferon-gamma” (IFN-g)
signature was developed in a discovery set of 19 patients
with melanoma treated with pembrolizumab in the Phase
1b KEYNOTE-001 study (NCT01295827) and was later
complemented with a 28-gene preliminary “expanded
immune” signature. These 2 signatures were subsequently
tested and refined in an independent cohort of 62 addi-
tional patients with melanoma treated in KEYNOTE-001.
Further evaluation of the refined signatures was performed
in 43 patients with head and neck squamous cell carcinoma
(HNSCC) and 33 patients with gastric cancer enrolled in
the Phase 1b KEYNOTE-012 study (NCT01848834).
Results
In the melanoma validation set, the IFN-g and expanded
immune signatures were significantly correlated with
ORR (P=0.047 and 0.027) and PFS (P=0.016 and 0.015).
The IFN-g signature was refined from 10 genes to 6,
and the expanded immune signature from 28 genes to
18. Two new signatures enriched in T cell markers and
MHC class I and II genes were enumerated based on
analysis of top-ranked genes on the platform in mela-
noma samples: “TCR signaling” (13 genes) and “de
novo” (33 genes). All signatures were independently
tested in HNSCC and gastric cancer and found to be
significantly correlated with clinical benefit (Table 1).
Tumors lacking an immune phenotype, as suggested by
low values of signature scores, did not respond to pem-
brolizumab. Some non-responders had scores similar to
those of responders, suggesting an immune phenotype is
necessary but not sufficient for response.
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Table 1 Nominal 1-sided P values for ORR and PFS
calculated from logistic and Cox regression, respectively,
using signature score as a continuous variable.
Signature HNSCC Gastric Cancer
ORR PFS ORR PFS
IFN-l 0.005 <0.001 0.077 0.032
TCR signaling 0.071 0.002 0.034 0.024
Expanded immune 0.015 <0.001 0.062 0.049
De novo 0.018 <0.001 0.068 0.037
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Conclusions
Immune-related gene expression signatures composed of
genes associated with T cell cytotoxic function, antigen
presentation machinery, and IFN-g signaling represent
reproducible and sensitive tools that define common fea-
tures of the immune microenvironment associated with
response to pembrolizumab across multiple tumor types.
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